Revolution Medicines, Inc. (RVMD)
Largest Insider Buys in Sector
RVMD Stock Price History Chart
RVMD Stock Performance
About Revolution Medicines, Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the …
Insider Activity of Revolution Medicines, Inc.
Over the last 12 months, insiders at Revolution Medicines, Inc. have bought $60M and sold $24.81M worth of Revolution Medicines, Inc. stock.
On average, over the past 5 years, insiders at Revolution Medicines, Inc. have bought $28.61M and sold $88.09M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Schroeder Thilo (director) — $120M.
The last purchase of 1,304,347 shares for transaction amount of $60M was made by Schroeder Thilo (director) on 2024‑12‑05.
List of Insider Buy and Sell Transactions, Revolution Medicines, Inc.
| 2024-12-16 | Sale | See Remarks | 11,714 0.0065% | $45.40 | $531,860 | -0.22% | ||
| 2024-12-16 | Sale | See Remarks | 4,663 0.0026% | $45.40 | $211,718 | -0.22% | ||
| 2024-12-16 | Sale | Chief Operating Officer | 4,329 0.0024% | $45.40 | $196,553 | -0.22% | ||
| 2024-12-16 | Sale | Chief Financial Officer | 2,635 0.0015% | $45.40 | $119,639 | -0.22% | ||
| 2024-12-16 | Sale | General Counsel | 1,599 0.0009% | $45.40 | $72,601 | -0.22% | ||
| 2024-12-05 | director | 1.3M 0.7544% | $46.00 | $60M | -4.52% | |||
| 2024-11-15 | Sale | General Counsel | 2,554 0.0015% | $55.13 | $140,811 | -12.66% | ||
| 2024-11-13 | Sale | See Remarks | 16,666 0.0099% | $58.65 | $977,509 | -17.03% | ||
| 2024-11-06 | Sale | General Counsel | 6,000 0.0037% | $60.00 | $360,000 | -10.02% | ||
| 2024-11-04 | Sale | See Remarks | 50,900 0.0301% | $55.56 | $2.83M | -1.32% | ||
| 2024-11-01 | Sale | See Remarks | 19,100 0.0114% | $55.02 | $1.05M | +0.74% | ||
| 2024-10-31 | Sale | director | 5,000 0.003% | $54.14 | $270,715 | +3.05% | ||
| 2024-10-14 | Sale | See Remarks | 16,666 0.0113% | $49.49 | $824,804 | +2.60% | ||
| 2024-10-11 | Sale | See Remarks | 30,000 0.0206% | $50.36 | $1.51M | -0.03% | ||
| 2024-10-11 | Sale | Chief Operating Officer | 50,000 0.0344% | $50.34 | $2.52M | -0.03% | ||
| 2024-10-11 | Sale | Chief Financial Officer | 10,000 0.0069% | $50.30 | $502,979 | -0.03% | ||
| 2024-10-11 | Sale | General Counsel | 6,000 0.0041% | $50.17 | $301,027 | -0.03% | ||
| 2024-10-08 | Sale | director | 5,200 0.0034% | $48.02 | $249,716 | +1.33% | ||
| 2024-10-01 | Sale | See Remarks | 10,000 0.0061% | $44.93 | $449,322 | +11.16% | ||
| 2024-09-16 | Sale | See Remarks | 11,715 0.007% | $44.19 | $517,631 | +10.81% |
Insider Historical Profitability
| Schroeder Thilo | director | 2096612 1.1498% | $44.06 | 15 | 0 | +9.37% |
| Flynn James E | 10 percent owner | 1297589 0.7116% | $44.06 | 1 | 0 | +14.18% |
| Kim Lorence H. | 60500 0.0332% | $44.06 | 1 | 0 | +5.12% |
Institutional Investor Ownership
| The Vanguard Group | $475.62M | 8.94 | 14.76M | +0.84% | +$3.96M | 0.01 | |
| Wellington Management Company | $474.26M | 8.92 | 14.71M | -1.13% | -$5.39M | 0.08 | |
| BlackRock | $396.69M | 7.46 | 12.31M | -4.99% | -$20.83M | 0.01 | |
| Baker Bros Advisors LP | $243.31M | 4.58 | 7.55M | +46.63% | +$77.37M | 1.75 | |
| Farallon Capital | $241.98M | 4.55 | 7.51M | +11.45% | +$24.85M | 1.7 |